Plancorp LLC Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Plancorp LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 899 shares of the biopharmaceutical company’s stock after selling 22 shares during the quarter. Plancorp LLC’s holdings in Regeneron Pharmaceuticals were worth $640,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Mizuho Securities USA LLC grew its holdings in Regeneron Pharmaceuticals by 45.0% in the fourth quarter. Mizuho Securities USA LLC now owns 9,977 shares of the biopharmaceutical company’s stock worth $7,107,000 after purchasing an additional 3,096 shares during the last quarter. Quantbot Technologies LP grew its holdings in Regeneron Pharmaceuticals by 266.7% in the fourth quarter. Quantbot Technologies LP now owns 528 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 384 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 15 shares during the period. DCF Advisers LLC lifted its stake in shares of Regeneron Pharmaceuticals by 14.8% during the fourth quarter. DCF Advisers LLC now owns 8,900 shares of the biopharmaceutical company’s stock worth $6,340,000 after buying an additional 1,150 shares during the period. Finally, Douglass Winthrop Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 70.1% during the fourth quarter. Douglass Winthrop Advisors LLC now owns 364 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 150 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ REGN opened at $658.48 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock has a market cap of $71.99 billion, a PE ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $689.43 and a 200 day moving average of $815.71.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $11.86 EPS. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.53%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Finally, Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.